



## PRESS RELEASE

Axxam enters into a research collaboration with The University of Texas MD Anderson Cancer Center for Assay Development and High Throughput Screening of selected targets in oncology

**June 18<sup>th</sup>, 2015 – Axxam SpA (Milan/Italy)**, a leading provider of discovery services, has entered into a multi-year collaboration with the Institute for Applied Cancer Science (IACS) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify lead chemical matters against novel oncology targets provided by MD Anderson. The collaboration leverages Axxam's expertise in assay development, Axxam's fully automated screening platforms and access to Axxam's novel compound collection Axx<sup>Div2.0</sup>. The collaboration builds on a strong working relationship between Axxam and MD Anderson.

Stefan Lohmer, co-founder and Chief Executive Officer at Axxam, commented: "Axxam is very pleased to continue our excellent working relationship with MD Anderson and see this agreement as further validation that our focus on science, interactive client collaborations, and continuous investment in our screening capabilities are vital to delivering high quality results and successful outcomes. We are looking forward to collaborating intensively and successfully with our colleagues at MD Anderson in order to set the ground for new cancer therapies".

Phil Jones, Head of Drug Discovery at IACS, commented that "This partnership has proved to be invaluable in finding novel starting points for a number of small molecule drug discovery projects, and we are delighted to continue the excellent relationship on future programs".

**About Axxam SpA** ([www.axxam.com](http://www.axxam.com))

*Axxam SpA is a privately owned contract research and discovery company located at the Science Park Openzone in Bresso (Milan, Italy). The Company is a leading provider of integrated discovery services for the entire Life Sciences industries as: Pharmaceutical, Crop protection, Animal health, Cosmetics and Nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies including: assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need.*